Leerink Partnrs Issues Positive Outlook for Natera Earnings

Natera, Inc. (NASDAQ:NTRA) – Analysts at Leerink Partnrs boosted their FY2024 EPS estimates for Natera in a note issued to investors on Tuesday, January 21st. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn ($1.27) per share for the year, up from their prior estimate of ($1.61). The consensus estimate for Natera’s current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Natera’s Q4 2024 earnings at ($0.16) EPS, Q1 2025 earnings at ($0.36) EPS, Q2 2025 earnings at ($0.31) EPS and Q4 2025 earnings at ($0.19) EPS.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Tuesday, November 12th. The medical research company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.31. The business had revenue of $439.80 million during the quarter, compared to analyst estimates of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. Natera’s quarterly revenue was up 63.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.95) EPS.

Other research analysts have also issued reports about the stock. Robert W. Baird upped their price objective on shares of Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. StockNews.com lowered shares of Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. Piper Sandler upped their target price on Natera from $150.00 to $200.00 and gave the stock an “overweight” rating in a report on Monday, November 18th. Guggenheim increased their target price on Natera from $170.00 to $200.00 and gave the stock a “buy” rating in a research report on Friday, January 17th. Finally, Craig Hallum lifted their price target on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $160.63.

Natera Trading Up 2.7 %

Shares of NTRA stock opened at $171.93 on Thursday. The stock has a fifty day moving average of $165.35 and a 200 day moving average of $135.41. Natera has a 52 week low of $62.96 and a 52 week high of $183.00. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33.

Institutional Trading of Natera

Large investors have recently made changes to their positions in the stock. Blue Trust Inc. grew its position in Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock worth $30,000 after purchasing an additional 97 shares during the period. Quarry LP increased its position in Natera by 148.4% during the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares during the last quarter. Versant Capital Management Inc lifted its holdings in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 166 shares during the period. Covestor Ltd boosted its position in Natera by 34.3% in the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after purchasing an additional 95 shares during the last quarter. Finally, GAMMA Investing LLC increased its position in shares of Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock valued at $55,000 after purchasing an additional 106 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, CFO Michael Burkes Brophy sold 691 shares of the stock in a transaction on Friday, October 25th. The stock was sold at an average price of $118.81, for a total transaction of $82,097.71. Following the sale, the chief financial officer now directly owns 72,709 shares of the company’s stock, valued at $8,638,556.29. This trade represents a 0.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Solomon Moshkevich sold 1,196 shares of the business’s stock in a transaction dated Monday, October 28th. The stock was sold at an average price of $118.21, for a total value of $141,379.16. Following the completion of the transaction, the insider now directly owns 110,695 shares of the company’s stock, valued at approximately $13,085,255.95. This trade represents a 1.07 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 224,824 shares of company stock valued at $36,912,749. Insiders own 7.60% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.